Recombinant Mycobacterium bovis bacillus Calmette-Guérin (BCG) expressing mouse IL-18 augments Th1 immunity and macrophage cytotoxicity.
about
Novel immunotherapeutic approaches to the treatment of urothelial carcinomaEvolving immunotherapy strategies in urothelial cancerRecombinant Bacille Calmette-Guérin coexpressing Ag85B-IFN-γ enhances the cell-mediated immunity in C57BL/6 mice.Identification and characterization of an SKN7 homologue in Cryptococcus neoformans.Immunomodulatory effects of recombinant BCG expressing MSP-1C of Plasmodium falciparum on LPS- or LPS+IFN-γ-stimulated J774A.1 cellsRecombinant BCG as a vaccine vehicle to protect against tuberculosis.Th1 cytokine-secreting recombinant Mycobacterium bovis bacillus Calmette-Guérin and prospective use in immunotherapy of bladder cancer.Co-immunization of plasmid DNA encoding IL-12 and IL-18 with Bacillus Calmette-Guérin vaccine against progressive tuberculosisSecretion of functional monocyte chemotactic protein 3 by recombinant Mycobacterium bovis BCG attenuates vaccine virulence and maintains protective efficacy against M. tuberculosis infectionAntitumor effects of human interferon-alpha 2b secreted by recombinant bacillus Calmette-Guérin vaccine on bladder cancer cells.Urinary bladder epithelium antigen induces CD8+ T cell tolerance, activation, and autoimmune response.Effects of DNA- and Mycobacterium bovis BCG-based delivery of the Flt3 ligand on protective immunity to Mycobacterium tuberculosis.IL-18 does not increase allergic airway disease in mice when produced by BCG.Independent Replication of Published Germline Polymorphisms Associated with Urinary Bladder Cancer Prognosis and Treatment ResponseNonmuscle invasive bladder cancer: a primer on immunotherapy.Promises and challenges for the development of Listeria monocytogenes-based immunotherapies.A novel subset of helper T cells promotes immune responses by secreting GM-CSFIs intranasal vaccination a feasible solution for tuberculosis?MUC1-based recombinant Bacillus Calmette-Guerin vaccines as candidates for breast cancer immunotherapy.Mycobacterium bovis bacillus Calmette-Guérin-induced macrophage cytotoxicity against bladder cancer cells.The mechanism of action of BCG therapy for bladder cancer--a current perspective.Recombinant bacillus Calmette-Guérin in urothelial bladder cancer immunotherapy: current strategies.Recombinant Mycobacterium bovis BCG for immunotherapy in nonmuscle invasive bladder cancer.Mycobacterium bovis Bacillus Calmette-Guérin Alters Melanoma Microenvironment Favoring Antitumor T Cell Responses and Improving M2 Macrophage Function.Auxotrophic recombinant Mycobacterium bovis BCG overexpressing Ag85B enhances cytotoxicity on superficial bladder cancer cells in vitro.Interleukin-10 inhibits Mycobacterium bovis bacillus Calmette-Guérin (BCG)-induced macrophage cytotoxicity against bladder cancer cells.BCG and protection against inflammatory and auto-immune diseases.Dendritic Cell Activity Driven by Recombinant Mycobacterium bovis BCG Producing Human IL-18, in Healthy BCG Vaccinated AdultsRecombinant BCG coexpressing Ag85B, CFP10, and interleukin-12 induces multifunctional Th1 and memory T cells in mice.Next-Generation Vaccines Based on Bacille Calmette-Guérin.Deletion of BCG Hip1 protease enhances dendritic cell and CD4 T cell responses.
P2860
Q26744347-63EB3FF4-78A3-461F-B2B8-E9A9BE372F58Q26823557-5F9E3B1C-01C8-4052-BE59-B8281289631AQ33724142-8365D49C-D006-44C7-81D7-6CCF6DFA0BEBQ33946817-27D6F5D2-E6D5-433E-8418-A20BD803DB70Q34291036-04785DB1-FD26-4CDA-8287-B8A24D20E9DFQ34518560-A6AC92D1-61E7-4CD8-A82B-78765196AEC1Q35215350-B9B2E8E3-C955-4493-9139-8920712DFE60Q35561894-B4A6689D-BCD5-46AC-ACED-41776B33C891Q35689094-9F5CD70B-CEF8-4C63-A5D6-2ADAEA40A554Q35946382-AA3CF8DF-7AF6-40BE-B71D-765873BAA7FEQ36131259-A8A5630F-B3A3-49B7-A1A7-7B5757575535Q36313882-B8485AF0-7BE7-417D-9B20-D8CA2C7619A3Q36449578-B0998662-A868-4291-9D83-3305BAEE144EQ37054113-5B142CD9-E8CE-46F2-8201-0B02ADA96AB7Q37094072-6251157C-60FA-4153-B47A-FC78D99F3C1EQ37259634-8031F22A-EA11-45EC-B1BA-363BF062184FQ37299468-E0D8803C-AA9B-483F-B767-3C9BD35C8C76Q37316013-94DF3FA0-F988-4EAB-8AF4-2F00EFD3C64DQ37737313-25A66C38-ED9D-4607-85CC-4D1F23B53990Q37791443-2C3DDBA5-275D-4474-802D-E84A448B833BQ38184849-6BC81A5F-FAAC-448D-8837-4568719E0F78Q38251141-8CC55F7C-E648-4AB3-BFD9-7C029E358351Q38385719-ED627940-51FC-4655-B0B9-A197E8C0936EQ38604832-A476181A-FF96-4A48-A42A-B531FD9495F8Q39262557-F3411688-8627-46AB-9BAF-27249676911DQ39740932-C75A6E28-5255-447E-9D31-CA0865C8224FQ40203403-A4560F32-4224-4920-A7B6-D0E520B85695Q41015596-54539CB9-CB39-40A1-B4FA-5EEB579E2C46Q43791358-0EEADB95-7164-4664-B744-854D56BF3B20Q49829375-3409FC7E-554F-4C20-8BB2-AF5EEF2F7FECQ49973045-C359DCF3-088F-40D6-9477-904B7DFD15FB
P2860
Recombinant Mycobacterium bovis bacillus Calmette-Guérin (BCG) expressing mouse IL-18 augments Th1 immunity and macrophage cytotoxicity.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Recombinant Mycobacterium bovi ...... y and macrophage cytotoxicity.
@en
type
label
Recombinant Mycobacterium bovi ...... y and macrophage cytotoxicity.
@en
prefLabel
Recombinant Mycobacterium bovi ...... y and macrophage cytotoxicity.
@en
P2093
P2860
P1476
Recombinant Mycobacterium bovi ...... ty and macrophage cytotoxicity
@en
P2093
P2860
P356
10.1111/J.1365-2249.2004.02522.X
P577
2004-07-01T00:00:00Z